Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1212/WNL.0b013e3182662084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biological Diagnosis of Alzheimer's Disease Based on Amyloid Status: An Illustration of Confirmation Bias in Medical Research?
Int J Mol Sci
December 2023
AgenT SAS, 4 Rue Pierre Fontaine, 91000 Evry-Courcouronnes, France.
Alzheimer's disease (AD) was first characterized by Dr. Alois Alzheimer in 1906 by studying a demented patient and discovering cerebral amyloid plaques and neurofibrillary tangles. Subsequent research highlighted the roles of Aβ peptides and tau proteins, which are the primary constituents of these lesions, which led to the amyloid cascade hypothesis.
View Article and Find Full Text PDF18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
Cochrane Database Syst Rev
November 2017
Iberoamerican Cochrane Centre, C/ Sant Antoni Maria Claret 167, Pavelló 18 Planta 0, Barcelona, Barcelona, Spain, 08025.
Background: F-florbetapir uptake by brain tissue measured by positron emission tomography (PET) is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly demonstrated by excluding Alzheimer's pathology in an established dementia diagnosis. However, the National Institute on Aging and Alzheimer's Association (NIA-AA) revised the diagnostic criteria for Alzheimer's disease and confidence in the diagnosis of mild cognitive impairment (MCI) due to Alzheimer's disease may be increased when using amyloid biomarkers tests like F-florbetapir.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!